WuXi STA to Build New Manufacturing Campus
WuXi STA’s Delaware campus will contain clinical and commercial manufacturing capabilities for small molecules and novel molecular modalities.
WuXi STA, a contract development and manufacturing organization, and Delaware Prosperity Partnership announced plans for a pharmaceutical manufacturing campus in Middletown, Del.
Expected to open in 2024, the 190-acre campus in Middletown will be WuXi STA’s second site in the United States and will house pharmaceutical clinical and commercial manufacturing. The location will be the company’s eighth global manufacturing facility.
The company aims to bring 500 full-time positions to the Delaware complex by 2026, which has the potential to expand to a total workforce exceeding 1000 employees.
WuXi STA provides pharmaceutical development and manufacturing for more than 470 partners worldwide, covering small molecules and novel molecular modalities such as oligonucleotide, peptide, and complex conjugates.
Source: STA Pharma
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
